Key points are not available for this paper at this time.
Introduction 0.05). We discovered functional variants in genes, including CD36, MMRN2, EPHB2, PLAUR, and RAPGEF3, which are enriched in the angiogenesis pathway. Phenotype-centric gene variant analysis underscored the role of MMRN2, a key player in angiogenesis (p0.001). MMRN2 (Multimerin-2) is a crucial regulator of endothelial cell movement, functioning as a negative modulator of angiogenesis by inhibiting KDR activation through its interaction with VEGFA. Conclusions: Rare functional variants may act as phenotype modifiers, potentially modulating the trajectory of DR into DME or PDR. Functional validation of these factors could represent new biomarkers and therapeutic targets for DR. Disclosure S. Rangasamy: None. F. Monickaraj: None. J.K. Sun: Research Support; Optovue, Boehringer-Ingelheim, Novo Nordisk, Roche Pharmaceuticals. Other Relationship; Roche Pharmaceuticals. Research Support; Physical Sciences, Inc, Boston Micromachines. L.P. Aiello: Advisory Panel; Novo Nordisk. Stock/Shareholder; Kalvista. Other Relationship; Optos. Consultant; Ceramedix. A. Das: None. Funding 5R01EY028606
Rangasamy et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: